Active substance |
17α,21‐dihydroxy‐16α‐methyl‐pregna‐1,4,9(11)‐triene‐3,20‐dione |
Holder |
Santhera Pharmaceuticals (Switzerland) |
Status |
Running |
Indication |
Duchenne Muscular Dystrophy in boys who are completing the VBP15-004 trial |
Public documents |
|
Information for the patient amendment 1 |
|
Last update |
09/04/2024 |
Vamorolone
Last updated on 13/09/2024